45.7K
Downloads
69
Episodes
AllergyTalk is a round-up of the latest in the field of allergy and immunology by the American College of Allergy, Asthma and Immunology. In each bi-monthly episode, hosts Gerald Lee, MD, and Merin Kalangara, MD, invite a guest to discuss key articles reviewed in the current issue of AllergyWatch.
Episodes
Thursday Oct 17, 2024
Thursday Oct 17, 2024
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 3: Maintenance and Reliever Therapy in Moderate to Severe Asthma
Host: Gerald B. Lee, MD, FACAAI
Experts: Leonard B. Bacharier, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI
Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: MART therapy, ICS/formoterol, FDA guidelines, pediatric application.
Learning Objectives:
- Expose the prevalence of asthma and exacerbations in the US
- Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
- Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
- Analyze the latest expert opinion on treatment of asthma to mitigate morbidity
Reference:
Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.
Speaker Disclosures:
Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose
Leonard B. Bacharier, MD, FACAAI
Advisor: DBV Technologies
Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi
Researcher: AstraZeneca, Sanofi
Speaker: Regeneron, Sanofi
Alan P. Baptist, MD, MPH, FACAAI
Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi
Researcher: AstraZeneca, Novartis, Regeneron
This podcast miniseries is supported by a grant from AstraZeneca.
Thursday Oct 17, 2024
Thursday Oct 17, 2024
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 2: Implementing an Anti-inflammatory Reliever in Mild Asthma
Host: Gerald B. Lee, MD, FACAAI
Experts: William C. Anderson III, MD, FACAAI, Leonard B. Bacharier, MD, FACAAI
Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: anti-inflammatory reliever (AIR), pediatric vs. adult patients, GINA guidelines, insurance challenges.
Learning Objectives:
- Expose the prevalence of asthma and exacerbations in the US
- Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
- Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
- Analyze the latest expert opinion on treatment of asthma to mitigate morbidity
Reference:
Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.
Speaker Disclosures:
Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose
William C. Anderson III, MD, FACAAI
Advisor: Genentech, Regeneron, Sanofi
Leonard B. Bacharier, MD, FACAAI
Advisor: DBV Technologies
Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi
Researcher: AstraZeneca, Sanofi
Speaker: Regeneron, Sanofi
This podcast miniseries is supported by a grant from AstraZeneca.
Thursday Oct 17, 2024
Thursday Oct 17, 2024
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 1: The Limitations of Bronchodilator Only Rescue Therapy
Host: Gerald B. Lee, MD, FACAAI
Experts: William C. Anderson III, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI
Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: pathophysiology, exacerbations, anti-inflammatory reliever (AIR), SMART therapy.
Learning Objectives:
- Expose the prevalence of asthma and exacerbations in the US
- Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
- Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
- Analyze the latest expert opinion on treatment of asthma to mitigate morbidity
Reference:
Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.
Speaker Disclosures:
Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose
William C. Anderson III, MD, FACAAI
Advisor: Genentech, Regeneron, Sanofi
Alan P. Baptist, MD, MPH, FACAAI
Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi
Researcher: AstraZeneca, Novartis, Regeneron
This podcast miniseries is supported by a grant from AstraZeneca.
Wednesday Sep 11, 2024
Wednesday Sep 11, 2024
Welcome to Season Three of Allergytalk!
Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Gut microbiota maturity mediates the protective effect of siblings on food allergy.
Duration of skin prick test refractory period following food-induced allergic reactions.
Please rate our podcast on Apple Podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis.
Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt
Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy
Wednesday Sep 11, 2024
Wednesday Sep 11, 2024
Welcome to Season Three of Allergytalk!
Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Outcomes of oral food challenges in a real-world setting, with predictors of outcomes.
Severe food allergy reactions are associated with α-tryptase.
Association of a Housing Mobility Program With Childhood Asthma Symptoms and Exacerbations.
Please rate our podcast on Apple Podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis.
Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt
Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy
Wednesday Aug 14, 2024
Wednesday Aug 14, 2024
Welcome to a Special Board Review Episode of AllergyTalk!
As the fall welcomes a new class of allergy/immunology fellows, the graduating fellows are studying for the fall ABAI board certification exam. I’m excited to be joined by the editorial team of the newly released 5th edition of the ACAAI Review of the Allergy & Immunology Boards, where we’ll talk about how you can prepare for the upcoming board exam!
Guests:
Joyce Yu, MD
Associate Professor of Pediatrics
Director, Food Allergy Center
Division of Allergy, Immunology and Rheumatology
Columbia University Irving Medical Center
Ben Prince, MD, MSCI
Associate Professor of Pediatrics
Associate Division Chief of Research
Division of Allergy-Immunology
The Ohio State University College of Medicine
Resources for Board Review:
ACAAI FIT and Board Review Resources (including the board review book)
AIM Self-Assessment: Volume One (2023)
AAAAI Allergy/Immunology Self Assessment
For information about CME credit, head over to http://education.acaai.org/allergytalk
Please rate our podcast on Apple Podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis.
Dr. Prince is a Data Monitoring Committee Member for Eli Lilly
Dr. Yu has no relevant disclosures.
Tuesday Jul 16, 2024
Tuesday Jul 16, 2024
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we joined by Dr. Sarah Spriet, DO, an allergist/immunologist at the Alexander T. Augusta Military Medical Center in Fort Belvoir, VA and an assistant editor of Allergy Watch. We will be reviewing the November-December 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Spriet have nothing to disclose
Dr. Fineman: Research: DBV, Novartis, Alladapt
Tuesday Jul 16, 2024
Tuesday Jul 16, 2024
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we joined by Dr. Sarah Spriet, DO, an allergist/immunologist at the Alexander T. Augusta Military Medical Center in Fort Belvoir, VA and an assistant editor of Allergy Watch. We will be reviewing the November-December 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
The protective effect of moderate maternal peanut consumption on peanut sensitization and allergy.
Hymenoptera venom skin testing: Adopting an accelerated test protocol.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Spriet have nothing to disclose
Dr. Fineman - Research: DBV, Novartis, Alladapt
Tuesday Jul 09, 2024
Tuesday Jul 09, 2024
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we joined by Dr. Tim Chow, an assistant professor at UT Southwestern and an assistant editor of Allergy Watch. We will be reviewing the July-August 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk . To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Racial and Ethnic Disparities in Allergen Immunotherapy Prescription for Allergic Rhinitis.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Chow have nothing to disclose
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Tuesday Jul 09, 2024
Tuesday Jul 09, 2024
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we joined by Dr. Tim Chow, an assistant professor at UT Southwestern and an assistant editor of Allergy Watch. We will be reviewing the July-August 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk. To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Wildfires and the Changing Landscape of Air Pollution-related Health Burden in California.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Chow have nothing to disclose
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst